What’s new in surfactant?
A clinical view on recent developments in neonatology and paediatrics

Jasper V. Been · Luc J. I. Zimmermann

Abstract Surfactant therapy has significantly changed clinical practice in neonatology over the last 25 years. Recent trials in infants with respiratory distress syndrome (RDS) have not shown superiority of any natural surfactant over another. Advancements in the development of synthetic surfactants are promising, yet to date none has been shown to be superior to natural preparations. Ideally, surfactant would be administered without requiring mechanical ventilation. An increasing number of studies investigate the roles of alternative modes of administration and the use of nasal continuous positive airway pressure to minimise the need for mechanical ventilation. Whether children with other lung diseases benefit from surfactant therapy is less clear. Evidence suggests that infants with meconium aspiration syndrome and children with acute lung injury/acute respiratory distress syndrome may benefit, while no positive effect of surfactant is seen in infants with congenital diaphragmatic hernia. However, more research is needed to establish potential beneficial effects of surfactant administration in children with lung diseases other than RDS. Furthermore, genetic disorders of surfactant metabolism have recently been linked to respiratory diseases of formerly unknown origin. It is important to consider these disorders in the differential diagnosis of unexplained respiratory distress although no established treatment is yet available besides lung transplantation for the most severe cases. Conclusion: Research around surfactant is evolving and recent developments include further evolution of synthetic surfactants, evaluation of surfactant as a therapeutic option in lung diseases other than RDS and the discovery of genetic disorders of surfactant metabolism. Ongoing research is essential to continue to improve therapeutic prospects for children with serious respiratory disease involving disturbances in surfactant.

Keywords Surfactant · Lung disease · Respiratory distress syndrome · Preterm · Therapy

Introduction

Surfactant is a complex mixture of lipids (90%) and proteins (10%) lining the epithelial surface of the lung. Four surfactant apoproteins have been described: the
hydrophobic surfactant protein B (SP-B) and SP-C and the hydrophilic SP-A and SP-D. Surfactant is synthesised by alveolar type II cells, stored in lamellar bodies that are exocytosed and taken up into the monolayer lining the alveolar epithelium.Traditionally, surfactant is recognised for its surface tension-lowering properties, by which alveolar collapse is prevented and gas exchange is facilitated. More recently, surfactant has been shown to have an important additional role in innate defence of the lung. Key players in this role are SP-A and D, members of the collectin family of proteins. Among their functions are binding, opsonisation and clearance of microbes from the lung and regulation of immune cell activity. Several reviews have addressed their role in detail [80, 148]. Evidence is now accumulating that SP-B, SP-C and the surfactant lipids may be involved in modulation of pulmonary inflammation as well [21, 30, 44, 71, 101, 117].

The relevance of surfactant for pulmonary physiology is highlighted by the respiratory distress syndrome (RDS) seen in preterm infants, caused by an absolute deficiency of surfactant. Affected infants experience respiratory insufficiency often requiring mechanical ventilation. The introduction of exogenous surfactant administration for these infants is generally regarded as one of the most important advancements in the field of neonatology, having significantly decreased neonatal mortality over the last 25 years. Nowadays, the potential benefit of surfactant therapy is evaluated in a wide range of respiratory disorders in both neonates and paediatric patients. Moreover, several disease entities of formerly unknown origin have recently been linked to genetic disorders of surfactant metabolism.

The purpose of this review is to give an overview of these and other recent developments in the field of surfactant, focusing on clinically relevant issues in neonatology and paediatrics.

**Surfactant in RDS**

In 1959 Avery and Mead established the relationship between surfactant deficiency and RDS seen in preterm infants [9]. Twenty years later, exogenous surfactant was successfully administered to preterm infants with RDS and shown to dramatically improve oxygenation in these babies [51]. In subsequent clinical trials, reductions in neonatal mortality and incidence of pneumothorax were found after surfactant administration [1]. Further trials found that early treatment is superior to late treatment [151], multiple doses are better than a single dose [122] and prophylactic surfactant is associated with better outcome than is rescue treatment [125]. Excellent reviews on the history of surfactant are available [57, 107].

In recent years knowledge of the in vivo surfactant metabolism in RDS patients has increased as a result of metabolic studies. Preterm infants were shown to have a decreased surfactant pool size with decreased synthesis but increased recycling of surfactant when compared to term infants [152]. Furthermore, it was found that both prenatal steroids and exogenous surfactant administration after birth stimulate endogenous surfactant synthesis [25, 26].

Recent developments in surfactant treatment for RDS include new comparative trials of natural surfactants, exploration of alternative modes of administration and evaluation of the use of nasal continuous positive airway pressure (nCPAP) either to decrease the need for surfactant or as an adjuvant therapy following surfactant administration. Moreover, much effort is put into the development of synthetic surfactants for treatment of respiratory distress. This topic is discussed separately.

**Natural surfactant**

In recent years, several clinical trials have compared the efficacy of different natural surfactants in the treatment of RDS. Natural surfactants are generally derived from either lung lavage or minced lung of bovine or porcine origin.

Four studies have compared beractant (Survanta) and poractant-α (Curosurf) [12, 93, 112, 126]. Curosurf was found to have a more rapid onset of action in most studies [93, 112, 126]. A meta-analysis of these studies plus one unpublished study suggested a significant decrease in neonatal mortality after Curosurf treatment [57]. However, three of these studies have compared a Curosurf dose of 200 mg/kg with a Survanta dose of 100 mg/kg [93, 112, 126]. When these studies were excluded from analysis, the difference in mortality after treatment with comparable doses of both surfactants was not statistically significant [57]. Malloy and colleagues reported a significant decrease in the incidence of persistent ductus arteriosus after Curosurf treatment [93]. None of the other studies found such an effect and it is unclear whether this difference may be explained by the dosing difference as well.

Baroutis and colleagues compared the effects of three different surfactant preparations: Curosurf, Survanta and Alveofact [12]. Treatment with either Curosurf or Alveofact was associated with a decrease in days on the ventilator, days on oxygen and hospital stay, but no significant improvement in morbidity and mortality. A more recent study comparing Survanta and Alveofact reported a decrease in chronic lung disease (CLD) with Survanta [59]. However, CLD was defined as oxygen need at 28 days of age, a definition that does not take into account the gestational age of the infant and is generally regarded to be imprecise and outdated. There was a decrease in days on the ventilator, days on oxygen and length of hospital stay.
with Survanta. The need for postnatal steroids was decreased in the Survanta group as well; however, their overall use was very high compared to current standards.

Two studies have compared Survanta and Infasurf (calfactant) for the treatment of RDS [7, 17]. The largest study compared the efficacy of the two surfactants for prophylactic administration as well as for rescue treatment [17]. Infasurf was found to have a more rapid effect, without having an effect on overall incidence of bronchopulmonary dysplasia (BPD) or mortality. Subgroup analysis showed a decrease in mortality after prophylactic Survanta treatment in infants under 600 g. A more recent, smaller study reported a decrease in number of doses required with Infasurf without any differences in outcome [7].

One small comparative trial was reported on bovine lipid extract surfactant (bLES) and Survanta [86]. Treatment with bLES was associated with a more rapid improvement in oxygenation, yet no effect on short-term outcome was seen.

In summary, most differences in effectiveness between natural surfactant preparations are short-lived. On the basis of currently available evidence, no preparation can clearly be considered superior to another with regard to morbidity and mortality. More data would be needed and future studies should include comparison of long-term outcome parameters. However, the clinical relevance of these differences is likely to be minimal; therefore, future studies should focus on more relevant aspects of surfactant therapy.

Timing of surfactant administration

Many studies have investigated the ideal timing of surfactant administration. Systematic reviews of earlier studies have found a decrease in the incidence of pneumothorax, pulmonary interstitial emphysema, CLD and mortality with early (within 2 h after birth) versus delayed surfactant administration [151] and a decrease in pneumothorax and mortality with prophylactic surfactant administration versus selective rescue therapy [125].

As stressed by Horbar and colleagues, these trials were conducted at a time when the use of antenatal steroid administration was much lower than it is today. Therefore, the observed difference between early and delayed surfactant therapy may be smaller in current practice [69]. A more recent trial still suggests a positive effect of early surfactant administration in intubated infants, albeit without any effect on morbidity and mortality [88].

Surfactant and nCPAP

An important issue is the use of nCPAP, either to prevent intubation and surfactant administration or to accelerate extubation after surfactant is given. A recent Cochrane review showed that intubation and early administration of surfactant followed by extubation to nCPAP was associated with decreased ventilator requirement, but an increase in number of surfactant administrations when compared to selective surfactant and continued ventilation [129]. No difference in BPD incidence was detected. Dani and colleagues later showed that, when intubated and given surfactant, infants may benefit from early extubation to nCPAP [40]. Whether intubation for the purpose of surfactant administration is favourable for larger preterms with mild to moderate RDS is questioned by a recent study showing an increase in median duration of ventilation with elective intubation and surfactant [46].

The potential of the initial use of nCPAP to prevent intubation and administration of surfactant is the subject of current studies. Potential side effects of intubation and high costs of surfactant administration might thus be avoided. Retrospective studies suggest that, when compared to early initiation of mechanical ventilation, early nCPAP decreases the incidence of intraventricular haemorrhage and improves survival but may increase the risk for necrotising enterocolitis when nCPAP fails [2, 5]. However, only part of the infants on early mechanical ventilation received surfactant. More recent data from Te Pas and colleagues suggest that even if early nCPAP fails, it may still result in a decreased BPD risk when compared to infants intubated in the delivery room [133].

Ideally, avoidance of intubation and subsequent mechanical ventilation would involve early initiation of nCPAP in combination with an alternative mode of surfactant administration. The combined use of early nCPAP and surfactant administration through a thin endotracheal catheter was reported to decrease the need for mechanical ventilation in very low birth weight infants [83]. Other potential alternatives for endotracheal administration include aerosolisation [48], bronchosopic administration [14], nasopharyngeal deposition [77] and administration of surfactant via a laryngeal mask [22, 136]. Clearly, controlled trials are needed to evaluate the safety of alternative modes of surfactant administration and the potential of a combined approach with early nCPAP to decrease the subsequent need for mechanical ventilation and improve outcome.

Synthetic surfactant

A major disadvantage of commercially available natural surfactants is their price. Therefore much effort has been put into development of synthetic surfactants. The basis of these preparations is a highly simplified phospholipid mixture. The lack of surfactant proteins is a disadvantage compared to natural surfactants. Natural surfactant preparations contain variable amounts of SP-B and SP-C that enhance surface tension-lowering properties and long favoured their use above synthetic preparations [123]. The
potential of several additives with surfactant protein-like properties to increase the efficacy of synthetic surfactant preparations is currently under evaluation.

Two synthetic surfactants containing such additives have been tested in clinical trials. One is Venticute, which contains recombinant SP-C (rSP-C). However, no trials involving Venticute in preterms with RDS have yet been published. The other, lucinactant (Survanta), is characterised by the addition of KL4 (sinapultide), a non-natural polypeptide that was designed to resemble SP-B [38]. Two trials comparing prophylactic use of Survanta to a natural surfactant in the treatment of RDS showed no differences in relevant outcome parameters [99, 121]. However, these trials were designed to show only ‘noninferiority’, and the study comparing three surfactant preparations was underpowered to detect a difference between Survanta and the natural surfactant Survanta [76].

So although synthetic surfactants, especially those with surfactant protein-like additives, have theoretical advantages over natural surfactants, to date none has been shown to be superior to natural preparations in comparative trials [38]. Yet the search for new synthetic surfactant protein analogues goes on. Recent data from in vitro and animal studies are promising regarding efficacy of different SP-B peptides, modified rSP-C with improved function and polymyxin B as possible future additives to synthetic surfactants [38]. Moreover, a group of additives capable of decreasing surfactant inactivation is under investigation, showing promising results. These include chitosan [153], hyaluronan [91, 92, 141], dextran [108] and polymyxin B [27, 130]. The potential of these additives lies in their use in RDS and meconium aspiration syndrome (MAS), where inactivation of surfactant by albumin and meconium respectively decreases its efficiency.

**Surfactant in other neonatal lung disease**

**Congenital diaphragmatic hernia (CDH)**

CDH is a serious disease associated with a mortality of 25–74%, primarily due to respiratory insufficiency [43]. Surfactant deficiency and dysfunction have been found in a lamb CDH model and respiratory failure in these animals improved after exogenous surfactant administration [143]. Data on surfactant pool size and function in infants with CDH are inconclusive [33, 35, 74, 85]. Only one small, randomised trial of surfactant in CDH patients on extracorporeal membrane oxygenation (ECMO) is available, showing no benefit [89]. Incidental reports do suggest a beneficial effect [10, 18, 53]. Recently, the CDH study group has retrospectively compared the outcomes of CDH infants that did and did not receive exogenous surfactant during admission. No difference was observed in term infants [137], while surfactant administration was associated with increased mortality in preterms [85]. However, this difference was not statistically significant after adjusting for gestational age and Apgar score. When only infants on ECMO were considered, surfactant still did not improve survival [36].

In conclusion, although surfactant therapy is incorporated in CDH treatment protocols in many centres, this strategy is not supported by evidence and is advised to be used only in the context of a randomised trial [43, 100].

**Meconium aspiration syndrome (MAS)**

Perinatal meconium aspiration affects surfactant function and metabolism in several ways. Meconium has an extremely high surface tension [116], inhibits surfactant function [11, 66, 98, 132] and causes pneumonitis with direct toxicity to alveolar type II cells [68, 109]. Furthermore, we have recently found decreased alveolar surfactant content and synthesis in infants with MAS [73].

Possible treatment options for MAS involving surfactant include bolus surfactant administration and lung lavage using either saline or diluted surfactant. Initial case series reported temporary improvements in oxygenation and a decreased need for ECMO after bolus surfactant treatment [8, 79]. Two randomised trials of bolus surfactant therapy have been published [47, 90]. A meta-analysis of these studies showed a decreased need for ECMO in surfactant-treated infants without any relevant improvement in outcome [124]. An important difference between the two studies was the timing of surfactant administration. With early treatment (within 6 h after birth), Findlay and colleagues did report additional beneficial effects, such as decreased air leaks and shorter duration of ventilation [47]. Based on current evidence, Dargaville and Mills advocate early administration of a surfactant known to resist meconium inactivation in severely affected infants, with repeated doses when needed [41].

Meconium can be effectively removed from the lung by lavage [87]. Most studies report a subsequent improvement in oxygenation above pre-lavage baseline, with earlier extubation and a decrease in pneumothorax incidence [41]. Two randomised controlled trials (RCT) of lavage therapy in MAS have been reported. Only limited data are available from one study, suggesting that surfactant lavage is better than saline lavage [110]. No significant differences were found between infants lavaged with Survanta and non-lavaged infants in the other trial [147]. However, additional studies are underway [41]. Further trials should focus on the comparison between bolus surfactant therapy and surfactant lavage.

In conclusion, infants with MAS seem to benefit from surfactant therapy when started early and repeated when
necessary. There is insufficient evidence as yet to support the use of surfactant lavage therapy for MAS outside the setting of a clinical trial [41]. As discussed earlier, the development of synthetic additives capable of decreasing meconium-induced surfactant inhibition may help to increase future efficacy of surfactant therapy for MAS.

Other neonatal lung diseases

Decreases in alveolar surfactant pool size and surfactant recycling have been described in chronically ventilated infants progressing to or suffering from BPD [32, 34, 127]. Therefore, surfactant might be beneficial in treating these infants. Indeed, incidental reports suggest short-term improvement after surfactant administration in chronically ventilated preterms, urging the need for further studies [15, 78, 96]. Other neonatal pulmonary disorders that may benefit from surfactant therapy include haemorrhagic pulmonary oedema [4] and neonatal pneumonia [64], yet once again only incidental reports addressing these issues are available.

Surfactant in paediatrics

Surfactant has been evaluated as a potential intervention in respiratory diseases beyond the neonatal period. Several reports have focused on the use of surfactant in acute respiratory distress syndrome (ARDS) or acute lung injury (ALI). In paediatric ARDS/ALI patients, acute improvement of oxygenation is seen with surfactant administration [65, 94, 97, 144–146]. No additional effects on outcome were noted in the first RCT [97]. In a more recent RCT in ventilated children with respiratory failure and bilateral radiographic abnormalities, treatment with Infasurf was associated with a decrease in mortality [145]. The mortality effect was greatest in the subgroup of infants (age <1 year), yet overall mortality was not significantly different after adjustment for immunocompromised status. Concerns about the study being underpowered and the increased incidence of hypotension and transient hypoxaemia in the treatment group warrant further evaluation before surfactant administration can be routinely recommended in paediatric ARDS/ALI [39]. An important determinant of surfactant response seems to be the nature of the lung injury causing the respiratory failure. Patients with direct lung injury may benefit more than do patients with indirect lung injury [145]. Future studies should address differences in ALI aetiology in the patients studied.

Several studies have investigated a possible role for surfactant in treatment of bronchiolitis. A recent systematic review evaluating three trials reported a significant decrease in duration of ventilation and of hospital admission with surfactant therapy [138]. However, it is generally felt that current evidence is insufficient to establish the role of surfactant suppletion in bronchiolitis and that additional trials are needed [42, 81, 138].

Surfactant disturbances have been described in a wider range of paediatric lung diseases and recent case series suggest a potential beneficial role for surfactant in the treatment of lobar atelectasis [82], intrapulmonary haemorrhage [55], Pneumocystis carinii pneumonia [37] and as an adjuvant therapy in ECMO patients [63]. Clearly, additional studies are needed to establish the safety and potential benefit of surfactant therapy in these disorders as well.

Genetic disorders of surfactant

SP-B deficiency

In recent years, several genetic disorders affecting surfactant metabolism have been identified. SP-B deficiency, first described in 1993 [104], is the most serious of these. It is a rare autosomal recessively inherited disease, in the majority of patients caused by the 121ins2 mutation [105]. SP-B is critical for lowering alveolar surface tension. Adding to the surfactant dysfunction caused by the deficiency of SP-B is the associated incomplete processing of SP-C [139]. In almost all cases a total absence of SP-B is present, which is invariably lethal [60]. Babies present with respiratory failure shortly after birth, only partially and transiently being responsive to exogenous surfactant administration. To date, the only therapeutic option for these patients is lung transplantation, which should be performed within weeks to months [61]. Recently, Palomar and colleagues reported that the outcome for lung transplantation in SP-B-deficient patients is comparable to patients transplanted for other reasons [111]. However, Hamvas reports that approximately half the families of children eligible for lung transplantation decline and another 30% of patients die awaiting transplantation [60].

SP-C-associated disease

In recent years, several mutations in the SP-C gene have been identified and connected to respiratory disease. The incidence of SP-C-associated disease appears to be considerably higher than that of SP-B deficiency [60]. This is partly due to the fact that SP-C mutations are inherited in a dominant manner [60]. On the other hand, approximately half of the disease-associated mutations are spontaneous mutations [60]. The most common mutation I73T, as well as most other mutations, results in production of misfolded SP-C that accumulates within the alveolar type II cell [13, 75, 140].
The presentation and characteristics of respiratory diseases resulting from SP-C mutations are diverse and unpredictable [60]. Patients carrying mutations may present anywhere between the newborn period and adulthood. In a large cohort of term newborns with unexplained respiratory disease, the incidence of SP-C gene mutations was shown to approach 10% [142]. Asymptomatic patients carrying SP-C mutations have also been identified [28, 134]. Newborns may present with RDS-like symptoms despite term birth. In paediatric patients interstitial lung disease may present with gradual onset of respiratory insufficiency, hypoxaemia and failure to thrive. Some patients remain stable or even improve, while others progress to respiratory insufficiency, eventually requiring lung transplantation.

No standard treatment for SP-C-associated disease is available. Some authors have seen clinical improvement after treatment with hydroxychloroquine [3, 114] or repeated lung lavage along with administration of corticosteroids and azathioprine [135], while others have not [19, 31]. Clearly, additional studies are needed to further investigate possible treatment options for SP-C-associated disease.

ABCA3-associated disease

The most recently discovered genetic disruption of surfactant metabolism is caused by mutations in the gene encoding for ABCA3 [119]. ABCA3 is an ATP-binding cassette (ABC) protein localised at the limiting membrane of lamellar bodies [102, 149]. In vitro studies show that depending on the mutation present, the mutant ABCA3 protein is either retained at the endoplasmic reticulum or is appropriately localised yet exhibits a decreased capacity to hydrolyse ATP [95]. The exact role of ABCA3 is unknown; however, other members of the ABCA protein family are involved in lipid transport [128]. A specific role for ABCA3 in lipid metabolism is further supported by the detection of reduced lung levels of phosphatidylglycerol and phosphatidylcholine subtypes in ABCA3 knockout mice, while levels of other phospholipids and cholesterol were unaffected [49]. Along with other studies, this work further suggests a key role for ABCA3 in lamellar body formation [29, 49, 103]. Abnormal lamellar body formation, surfactant deficiency and surfactant dysfunction have indeed been found in patients carrying ABCA3 mutations [20, 23, 52, 119].

Most patients with ABCA3 mutations described thus far presented in the neonatal period with progressive respiratory distress, often being lethal. Hydroxychloroquine and corticosteroids have been used in the management of ABCA3-associated disease, yet their efficiency in treating the disorder is unclear [23]. For these patients, lung transplantation is currently the only treatment option [24, 52]. However, Bullard and colleagues have recently stressed the fact that most patients described thus far were derived from highly selected populations of infants with unexplained severe respiratory distress [23]. The same group has identified ABCA3 mutations in paediatric patients with interstitial lung disease, suggesting that defects in ABCA3 may be involved in a greater range of respiratory diseases [24]. Research on ABCA3-associated respiratory disease is clearly evolving and knowledge about the disorder will increase in the near future.

We wish to underline the importance of considering genetic disorders of surfactant metabolism in the differential diagnosis of both unexplained respiratory failure and interstitial lung disease in the newborn period and beyond. When such a disorder is suspected in a patient, one should turn to a specialised laboratory for establishment of the diagnosis.

Surfactant protein polymorphisms and lung disease

In addition to the mutations described above, more common polymorphisms in surfactant proteins have been linked to both increased and decreased risks of developing neonatal and paediatric pulmonary disease. Genetic variants of the SP-B gene have been linked to increased risks for both respiratory distress [50, 62] and BPD [115]. Common SP-A alleles, in interaction with the SP-B Ile131Thr genotype, have been associated with RDS susceptibility, while others seem to decrease RDS risk [56, 58]. Recently, polymorphisms in SP-C genes have also been linked to RDS [84]. The susceptibility for respiratory syncytial virus (RSV) infection is altered by polymorphisms of SP-A and SP-D, known modulators of innate immunity. In addition, associations of surfactant protein polymorphisms with extrapulmonary diseases exist, such as recurrent ear infections [113] and meningococcal disease [72].

The relevance of these associations between surfactant protein haplotypes and neonatal and paediatric pulmonary and infectious diseases remains unclear. Associations may differ between populations, hence the finding of contrasting risk associations between SP-B polymorphisms and RDS [62]. Larger studies are clearly needed to confirm current findings. Possible future applications include individual risk determination and subsequent surfactant protein administration.

Future directions and conclusion

As highlighted in this review, substantial progression has been made in recent years considering the role of surfactant therapy in neonatal and paediatric lung diseases. However, many questions remain unanswered. Efforts should be made to investigate the roles of nCPAP and alternative administration routes for surfactant in the treatment of preterm infants. Further development of synthetic surfac-
tants to enhance their surface tension-lowering properties and capacity to withstand inactivation may increase future efficacy of surfactant therapy. More ideally, one should be able to stimulate endogenous surfactant synthesis in preterm infants, preferably antenatally. A potential candidate drug would be docosahexaenoic acid, which has been shown to stimulate synthesis of dipalmitoyl phosphatidylcholine, the major phospholipid in surfactant, in preterm mice when administered to the mother during pregnancy [16]. Another promising future application for surfactant is its use as a carrier for drug administration directly into the lung. In this way drugs are allowed to act locally with minimisation of unwanted systemic effects. Possible candidate drugs include immunosuppressants [54], vasodilators [106] and β-sympathomimetics [150]. Investigational drugs that have been administered in animal models using surfactant as a carrier include a 5-lipoxygenase inhibitor [6] and recombinant human Clara cell secretory protein (rhCC10) [118]. Both agents have been shown to decrease experimental lung injury in these models. The anti-inflammatory and antimicrobial characteristics of SP-A and SP-D make them attractive potential therapeutic agents as well. Administration of recombinant SP-D fragments in animal models results in enhanced pulmonary clearance of RSV [67], a reduced allergic response [45, 120, 131] and prevention of endotoxin shock [70]. However, SP-A and SP-D are very large and complex molecules, making construction of functional recombinant whole proteins extremely difficult if not impossible. Much more research is needed to evaluate a possible role for surfactant proteins in the treatment of inflammatory diseases. Furthermore, the general evolution of gene therapy involves potential applications in the genetic disorders of surfactant metabolism, primarily SP-B deficiency.

More than 25 years after the introduction of exogenous surfactant therapy, research around surfactant is still evolving. Surfactant remains a hallmark in the treatment of RDS, especially in very preterm infants. Future research should focus on potential ways to avoid intubation and mechanical ventilation and give surfactant via an alternative route. The therapeutic role of surfactant in other neonatal and paediatric lung diseases is less clear and needs further evaluation. Finally, genetic disorders of surfactant metabolism should be taken into account in the differential diagnosis of respiratory distress and interstitial lung disease in children.

References

1. Collaborative European Multicenter Study Group (1988) Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group. Pediatrics 82(5):683–691

2. Aly H, Massaro AN, Patel K, El-Mohandes AA (2005) Is it safer to intubate premature infants in the delivery room? Pediatrics 115(6):1660–1665

3. Amin RS, Wert SE, Baughman RP, Tomashefski JF Jr, Nogee LM, Brody AS, Hull WM, Whitsett JA (2001) Surfactant protein deficiency in familial interstitial lung disease. J Pediatr 139(1):85–92

4. Amizuka T, Shimizu H, Niida Y, Ogawa Y (2003) Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. Eur J Pediatr 162(10):697–702

5. Ammari A, Suri M, Milisavljevic V, Sahni R, Bateman D, Sanoeka U, Ruzal-Shapiro C, Wung JT, Polin RA (2005) Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr 147(3):341–347

6. Ankermann T, Reisner A, Wiemann T, Koehler H, Krams M, Krause MF (2006) Intrapulmonary application of a 5-lipoxygenase inhibitor using surfactant as a carrier reduces lung edema in a piglet model of airway lavage. Pediatr Pulmonol 41(5):452–462

7. Attar MA, Becker MA, Dechert RE, Domm SM (2004) Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial. J Perinatol 24(10):626–630

8. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL (1991) Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 87(1):101–107

9. Avery ME, Mead J (1959) Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child 97(5, Part 1):517–523

10. Bae CW, Jeong CK, Chung SJ, Choi YM, Oh SM, Lee TS, Shin OY (1996) Exogenous pulmonary surfactant replacement therapy in a neonate with pulmonary hypoplasia accompanying congenital diaphragmatic hernia—a case report. J Korean Med Sci 11(3):265–270

11. Bae CW, Takahashi A, Chida S, Sasaki N (1998) Morphology and function of pulmonary surfactant inhibited by meconium. Pediatr Res 44(2):187–191

12. Baroutis G, Kaleiyas J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C (2003) Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr 162(7–8):476–480

13. Beers MF, Mulgreta S (2005) Surfactant protein C biosynthesis and its emerging role in conformational lung disease. Annu Rev Physiol 67:663–696

14. Biban P, Benedetti M, Soffiati M, Ghizzi C, Zaglia F, Bolognani M, Bonetti P, Santuz P (2006) Surfactant instillation via bronchoscopy in preterm infants with respiratory distress syndrome (abstract). Europaediatrics

15. Bissinger R, Carlson C, Hulsey T, Eicher D (2004) Secondary surfactant deficiency in neonates. J Perinatol 24(10):663–666

16. Blanco PG, Freedman SD, Lopez MC, Ollero M, Comen E, Laposata M, Alvarez JG (2004) Oral docosahexaenoic acid given to pregnant mice increases the amount of surfactant in lung and amniotic fluid in preterm fetuses. Am J Obstet Gynecol 190(5):1369–1374

17. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR, Malloy MH, Brown DR, Holzman IR, Coghill CH, Carlo WA, Prunamik AK, McCaffree MA, Toubas PL, Laupart S, Grauny LL, Weatherstone KB, Seguin JH, Willett LD, Gutter GR, Mueller DH, Topper WH (1997) Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 100(1):31–38

18. Bos AP, Tibboel D, Hazebroek FW, Molenaar JC, Lachmann B, Gommers D (1991) Surfactant replacement therapy in high-risk congenital diaphragmatic hernia. Lancet 338(8777):1279
19. Brash C, Greise M, Tredano M, Johnen G, Ochs M, Rieger C, Mulgut A, Muller KM, Babau M, Beers MF (2004) Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J 24(1):30–39

20. Brash C, Schimanski S, Muhlfeld C, Barlage S, Langmann T, Aslanidis C, Böchter A, Dada A, Schrenk H, Mildenberger E, Prudden E, Ballmann M, Ochs M, Johnen G, Greise M, Schmitz G (2006) Alteration of the pulmonary surfactant system in full-term infants with hereditary ABCA3 deficiency. Am J Respir Crit Care Med 174(5):571–580

21. Bridges JP, Xu Y, Na CL, Wong HR, Weaver TE (2006) Adaptation and increased susceptibility to infection associated with constitutive expression of misfolded SP-C. J Cell Biol 172(3):395–408

22. Brimacombe J, Gandini D, Keller C (2004) The laryngeal mask airway for administration of surfactant in two neonates with respiratory distress syndrome. Paediatr Anaesth 14(2):188–190

23. Bullard JE, Wert SE, Nogee LM (2006) ABCA3 Deficiency: neonatal respiratory failure and interstitial lung disease. Semin Perinatol 30(6):327–334

24. Bullard JE, Wert SE, Whitsett JA, Dean M, Nogee LM (2005) ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med 172(8):1026–1031

25. Bunt JE, Cernelli VP, Darco Vaccinella JF, Hop WC, Sauer P, Zimmermann LJ (2000) The effect in premature infants of prenatal corticosteroids on endogenous surfactant synthesis as measured with stable isotopes. Am J Respir Crit Care Med 162(3 Pt 1):844–849

26. Bunt JE, Cernelli VP, Janssen DJ, Vaccinella JF, Hop WC, Sauer P, Zimmermann LJ (2000) Treatment with exogenous surfactant stimulates endogenous surfactant synthesis in premature infants with respiratory distress syndrome. Crit Care Med 28(10):3383–3388

27. Calkovska A, Some M, Linderholm B, Johansson J, Curstedt T, Robertson B (2005) Biophysical and physiological properties of porcine surfactant enriched with polymyxin B. Biol Neonate 88(2):101–108

28. Cameron HS, Somaschini M, Carrera P, Hamvas A, Whitsett JA, Wert SE, Deutsch G, Nogee LM (2005) A common mutation in the surfactant protein C gene associated with lung disease. J Pediatr 146(3):370–375

29. Cheung N, Madhesh M, Gonzalez LW, Zhao M, Yu K, Ballard PL, Shuman H (2006) Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J Biol Chem 281(14):9791–9800

30. Chiba H, Piboonpogonan S, Mitsuzawa H, Kuronuma K, Murphy RC, Voelker DR (2006) Pulmonary surfactant proteins and lipids as modulators of inflammation and innate immunity. Respirology 11 Suppl:S2–S6

31. Chibbar R, Shih F, Bagga M, Torlakovic E, Ramllali K, Skomro R, Cockcroft DW, Lemire EG (2004) Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. Mod Pathol 17(8):973–980

32. Cogo PE, Toffolo GM, Giacciardi A, Benetazzo A, Cobelli C, Cernelli VP (2005) Surfactant disaturated phosphatidylycholine kinetics in infants with bronchopulmonary dysplasia measured with stable isotopes and a two-compartment model. J Appl Physiol 99(1):323–329

33. Cogo PE, Zimmermann LJ, Meneghini L, Mainini N, Bordignon L, Suma V, Buffo M, Cernelli VP (2003) Pulmonary surfactant disaturated-phosphatidylcholine (DSPC) turnover and pool size in newborn infants with congenital diaphragmatic hernia (CDH). Pediatr Res 54(5):653–658

34. Cogo PE, Zimmermann LJ, Pesavento R, Sacchetto E, Burgihel A, Rosso F, Badon T, Verlato G, Cernelli VP (2003) Surfactant kinetics in preterm infants on mechanical ventilation who did and did not develop bronchopulmonary dysplasia. Crit Care Med 31(5):1532–1538

35. Cogo PE, Zimmermann LJ, Verlato G, Midrio P, Gucciardi A, Ori C, Cernelli VP (2004) A dual stable isotope tracer method for the measurement of surfactant disaturated-phosphatidylcholine line synthesis in infants with congenital diaphragmatic hernia. Pediatr Res 56(2):184–190

36. Colby CE, Lally KP, Hintz SR, Lally PA, Tibboel D, Moya FR, VanMeurs KP (2004) Surfactant replacement therapy on ECMO does not improve outcome in neonates with congenital diaphragmatic hernia. J Pediatr Surg 39(11):1632–1637

37. Creery WD, Hashimi A, Hutchinson JS, Singh RN (1997) Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. Pediatr Pulmonol 24(5):370–373

38. Curstedt T, Johansson J (2006) New synthetic surfactant-how and when? Biol Neonate 89(4):336–339

39. Czaja AS (2007) A critical appraisal of a randomized controlled trial: Willson et al: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury (JAMA 2005, 293:470–476). Pediatr Crit Care Med 8(1):50–53

40. Dani C, Bertini G, Pizzetti M, Cecchi A, Caviglioli C, Rubaltelli FF (2004) Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks’ gestation. Pediatrics 113(6):e560–e563

41. Dargaville PA, Milks JF (2005) Surfactant therapy for meconium aspiration syndrome: current status. Drugs 65(18):2569–2591

42. Davison C, Ventura K, Luchetti M, Randolph AG (2004) Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis. Pediatr Crit Care Med 5(5):482–489

43. Doyle NM, Lally KP (2004) The CDH Study Group and advances in the clinical care of the patient with congenital diaphragmatic hernia. Semin Perinatol 28(3):174–184

44. Epaud R, Ikegami M, Whitsett JA, Jobe AH, Weaver TE, Akinci HT (2003) Surfactant protein B inhibits endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol 28(3):373–378

45. Erpenbeck VJ, Ziegert M, Cavalet-Blanco D, Martin C, Baelder R, Glahn T, Braun A, Steinhalber W, Luettig B, Uhlig S, Hoymann HG, Krug N, Hohlfied JM (2006) Surfactant protein D inhibits early airway response in Aspergillus fumigatus-sensitized mice. Clin Exp Allergy 36(7):930–940

46. Escobedo MB, Gunel JK, Kennedy KA, Shattuck KE, Sanchez PJ, Seidner S, Hensley G, Cochran CK, Moya F, Morris B, Denson S, Stribley R, Naqvi M, Lasky RE (2004) Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial. J Pediatr 144(6):804–808

47. Findlay RD, Taeusch HW, Walther JF (1996) Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 97(1):48–52

48. Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Liu G (2006) A multicenter, pilot study of Aerosurf delivered via nasal CPAP to prevent RDS in pre-term neonates (abstract). E-PAS; 59: e563

49. Fitzgerald ML, Xavier R, Haley KJ, Welti R, Goss JL, Brown CE, FF (2004) Early extubation and nasal continuous positive airway pressure after surfactant treatment for respiratory distress syndrome among preterm infants <30 weeks’ gestation. Pediatrics 113(6):e560–e563

50. Floros J, Thomas NJ, Liu W, Papagaroufalis C, Xanthou M, Pereira S, Fan R, Guo X, Diangelo S, Pavlovic J (2006) Family-based association tests suggest linkage between surfactant protein B (SP-B) (and flanking region) and respiratory distress
87. Lam BC, Yeung CY (1999) Surfactant lavage for meconium aspiration syndrome: a pilot study. Pediatrics 103(5 Pt 1):1014–1018
88. Lefort S, Diniz EM, Vaz FA (2003) Clinical course of premature infants intubated in the delivery room, submitted or not to porcine-derived lung surfactant therapy within the first hour of life. J Matern Fetal Neonatal Med 14(3):178–197
89. Lotze A, Knight GR, Anderson KD, Hull WM, Whitsett JA, O’Donnell RM, Martin G, Bulas DI, Short BL (1994) Surfactant (beractant) therapy for infants with congenital diaphragmatic hernia on ECMO: evidence of persistent surfactant deficiency. J Pediatr Surg 29(3):407–412
90. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH (1998) Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survantta in Term Infants Study Group. J Pediatr 132(1):40–47
91. Lu KW, Goerke J, Clements JA, Tauesch HW (2005) Hyaluronan decreases surfactant inactivation in vitro. Pediatr Res 57(2):237–241
92. Lu KW, Goerke J, Clements JA, Tauesch HW (2005) Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res 58(2):206–210
93. Malloy CA, Nicoski P, Muraskas JK (1995) A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 94(6):779–784
94. Marraro GA, Luchetti M, Galassini EM, Abbiati G (1999) Natural surfactant supplementation in ARDS in paediatric age. Minerva Anestesiol 65(5 Suppl 1):92–97
95. Matsumura Y, Ban N, Ueda K, Inagaki N (2006) Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency. J Biol Chem 281(45):34503–34514
96. Merrill JD, Ballard PL, Hibbs AM, Godinez RI, Godinez MH, Luan X, Ryan R, Reynolds AM, Hamvas A, Spence K, Courtney S, Truong W, Poscheneg M, Ades A, Lisby DA, Ballard RA (2006) Booster surfactant therapy beyond the first week of life in ventilated extremely low gestational age infants (abstract). E-PAS; 2006 Conference Proceedings. Professional Services Dept., Ross Products, Columbus, OH, pp 259–264
97. Lu KW, Goerke J, Clements JA, Tauesch HW (2005) Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res 57(2):237–241
98. Moses D, Holm BA, Galassini EM, Abbiati G (1999) Natural surfactant supplementation in ARDS in paediatric age. Minerva Anestesiol 65(5 Suppl 1):92–97
99. Matsunuma Y, Ban N, Ueda K, Inagaki N (2006) Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency. J Biol Chem 281(45):34503–34514
100. Moyer JC, Schaitte T, Roll C, Schittmann JH, Bindl L, Schrod L, Reiss I, Kohl M, Demirakca S, Hentschel R, Paul T, Vierzig A, Gronke P, von seefeld H, Schumacher H, Gortner L (2003) Bronchial lavage with surfactant solution for meconium aspiration syndrome: physiological, inflammatory, and kinetic profiles. J Pediatr 149(4):548–553
101. Moyer JC, Schaitte T, Roll C, Schittmann JH, Bindl L, Schrod L, Reiss I, Kohl M, Demirakca S, Hentschel R, Paul T, Vierzig A, Gronke P, von seefeld H, Schumacher H, Gortner L (2003) Bronchial lavage with surfactant solution for meconium aspiration syndrome: physiological, inflammatory, and kinetic profiles. J Pediatr 149(4):548–553
102. Motta LM, Wert SE, Proffit SA, Hull WM, Whitsett JA (2000) Allelic heterogeneity in hereditary surfactant protein C deficiency. J Biol Chem 275(25):22147–22155
103. Nagata K, Yamamoto A, Ban N, Tanaka AR, Matsuo M, Kioka N, Inagaki N, Ueda K (2004) Human ABCA3, a product of a responsive gene for abca3 for fatal surfactant deficiency in newborns, exhibits unique ATP hydrolysis activity and generates intracellular multimellar vesicles. Biochem Biophys Res Commun 324(2):262–268
104. Nogee LM, de Mello DE, Dehner LP, Colten HR (1993) Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 326(6):406–410
105. Nogee LM, Wert SE, Proffit SA, Hull WM, Whitsett JA (2000) ABCA3 gene mutations in newborns with fatal surfactant deficiency. J Am Respir Crit Care Med 161(3 Pt 1):973–981
106. Obaid L, Johnson ST, Bigam DL, Cheung PY (2006) Intratracheal administration of sildenafil and surfactant alleviates the pulmonary hypertension in newborn piglets. Resuscitation 69(2):287–294
107. Obland M (2005) History of surfactant up to 1980. Biol Neonate 87(4):308–316
108. Ochs M, Schattler M, Stichtenoth G, Herting E (2006) Morphological alterations of exogenous surfactant inhibited by meconium can be prevented by dextran. Respir Res 7:86
109. Oelberg DG, Downey SA, Flynn MM (1990) Bile salt-induced intracellular Ca++ accumulation in type II pneumocytes. Lung 168(6):297–308
110. Ogawa Y (1997) Bronchial lavage with surfactant solution for the treatment of meconium aspiration syndrome. Hot topics in Neonatology ’97 Conference Proceedings. Professional Services Dept., Ross Products, Columbus, OH, pp 259–264
111. Palomar LM, Wert SE, Proffit SA, Hull WM, Whitsett JA (2000) Allelic heterogeneity in hereditary surfactant protein C deficiency. J Biol Chem 275(25):22147–22155
112. Ramanathan R, Luchetti M, Galassini EM, Abbiati G (1999) Natural surfactant supplementation in ARDS in paediatric age. Minerva Anestesiol 65(5 Suppl 1):92–97
113. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K (2004) A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 21(3):109–119
114. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K (2004) A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 21(3):109–119
115. Ramet M, Lofgren J, Alho OP, Hallman M (2001) Surfactant protein-A gene locus associated with recurrent otitis media. J Pediatr 138(2):266–268
116. Rosen DM, Waltz DA (2005) Hydroxylcholroquine and surfactant protein C deficiency. N Engl J Med 352(2):207–208
117. Rova M, Haataja R, Marttila R, Ollikainen V, Tammero O, Hallman M (2004) Data mining and multiparameter analysis of lung surfactant protein genes in bronchopulmonary dysplasia. Hum Mol Genet 13(11):1095–1104
118. Ryan MA, Haataja R, Marttila R, Ollikainen V, Tammero O, Hallman M (2004) Data mining and multiparameter analysis of lung surfactant protein genes in bronchopulmonary dysplasia. Hum Mol Genet 13(11):1095–1104
119. Rubin BK, Tomkiewicz R, Netropsin ME, Essa D (1996) The surface and transport properties of meconium and reconstituted meconium solutions. Pediatr Res 40(6):834–838
120. Ryan MA, Akinbi HT, Serrano AG, Perez-Gil J, Wu H, McCormack FX, Weaver TE (2006) Antimicrobial activity of native and synthetic surfactant protein B peptides. J Immunol 176(1):416–425
121. Shashikant BN, Miller TL, Welch RW, Pilon AL, Shaffer TH, Wolfsen MR (2005) Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: physiological, inflammatory, and kinetic profiles. J Appl Physiol 99(6):2204–2211
122. Shulenin S, Nogee LM, Amnino T, Wert SE, Whitsett JA, Dean M (2004) ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 350(13):1296–1303
123. Singh M, Madan T, Waters P, Parida SK, Sarma PU, Kishore U (2003) Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens. Immunol Lett 86(3):299–307
124. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadinowski J, Hajdú J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d’Argostino R (2005) A multicenter, randomized, controlled trial of lucinactant versus poractant alfa
among very premature infants at high risk for respiratory distress syndrome. Pediatrics 115(4):1030–1038
122. Soll RF (2000) Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2:CD000141
123. Soll RF, Blanco F (2001) Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2:CD000144
124. Soll RF, Dargaville P (2000) Surfactant for meconium aspiration syndrome in full term infants. Cochrane Database Syst Rev 2:CD002054
125. Soll RF, Morley CJ (2001) Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2:CD000510
126. Speer CP, Gefeller O, Gronke P, Laukotter E, Roll C, Hanssler L, Harms K, Herting E, Boenisch H, Windeler J (1995) Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 72(1):F8–F13
127. Spence KL, Zozobrado JC, Patterson BW, Hamvas A (2005) Substrate utilization and kinetics of surfactant metabolism in evolving bronchopulmonary dysplasia. J Pediatr 147(4):480–485
128. Steklova J, Pohledne R, Hubacek JA (2004) ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol Res 53(3):235–243
129. Stevens TP, Blennow M, Soll RF (2004) Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 3:CD003063
130. Stichtenoth G, Jung P, Walter G, Johannsson J, Robertson B, Curstedt T, Herting E (2006) Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatr Res 59(3):407–411
131. Strong P, Townsend P, Mackay R, Reid KB, Clark HW (2003) A recombinant fragment of human SP-D reduces allergic responses in mice sensitized to house dust mite allergens. Clin Exp Immunol 134(2):181–187
132. Sun B, Curstedt T, Robertson B (1993) Surfactant inhibition in experimental meconium aspiration. Acta Paediatr 82(2):182–189
133. Talar AB, Lopriore E, Engbers MJ, Walther FJ (2007) Early respiratory management of respiratory distress syndrome in very preterm infants and bronchopulmonary dysplasia: a case-control study. PLoS ONE 2:e192
134. Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, Speer M, Schwartz DA, Gaddipati R, Marney A, Johnson J, Roberts R, Sekar KC, Mastriotanni L, Marcy B, Revak SD, Tsai H, Cochrane CG (2002) A multicenter, randomized, controlled trial comparing Surfaxin (Lucpectant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 109(6):1081–1087
135. Wright JR (2005) Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 5(1):58–68
136. Yamano G, Funahashi H, Kawanami O, Zhao LX, Ban N, Uchida Y, Morohoshi T, Ogawa J, Shioda S, Inagaki N (2001) ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett 508(2):221–225
137. Veitney K, Haroon M, Davison C (2006) Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev 3:CD005150
138. Vorbroeker DK, Proffitt SA, Nogee LM, Whitsett JA (1995) Ablation of surfactant protein C in hereditary SP-B deficiency. Am J Physiol 268(4 Pt 1):L647–L656
139. Wang WJ, Mulugeta S, Russo SJ, Beers MF (2003) Deletion of exon 4 from human surfactant protein C results in agressive formation and generation of a dominant negative. J Cell Sci 116 (Pt 4):683–692
140. Wang X, Sun Z, Qian L, Guo C, Yu W, Wang W, Lu K, Taeusch HW, Sun B (2006) Effects of hyaluronan-fortified surfactant in ventilated premature piglets with respiratory distress. Biol Neonate 89(1):15–24
141. Wd S, Deutsch G, Hamvas A, Whitsett J, Nogee L (2005) Mutations in the surfactant protein C gene (SFTPC) are associated with acute and chronic lung disease in full term infants. Am J Respir Crit Care Med Abstr 2:A23
142. Wilcoxon DT, Glick PL, Karamanoukian H, Rossman J, Morin FC 3rd, Holm BA (1994) Pathophysiology of congenital diaphragmatic hernia. V. Effect of exogenous surfactant therapy on gas exchange and lung mechanics in the lamb congenital diaphragmatic hernia model. J Pediatr 124(2):289–293
143. Wilsson DF, Jiao JH, Bauman LA, Zantisky A, Craft H, Dockery K, Conrad D, Dalton H (1996) Calf’s lung surfactant extract in acute hypoxic respiratory failure in children. Crit Care Med 24 (8):1316–1321
144. Wilsson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pons S, Jacobs BR, Jefferson LS, Conaway MR, Egan EA (2005) Effect of exogenous surfactant (calfant) in pediatric acute lung injury: a randomized controlled trial. JAMA 293(4):470–476
145. Willson DF, Zantisky A, Bauman LA, Dockery K, James RL, Conrad D, Craft H, Novotny WE, Egan EA, Dalton H (1999) Instillation of calf lung surfactant extract (calfant) is beneficial in pediatric acute hypoxic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network. Crit Care Med 27 (1):188–195
146. Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, Sekar KC, Bernstein G, Kesler M, Visser VE, Merritt TA, Mannino FL, Mastriotanni L, Marcy B, Revak SD, Tsai H, Cochrane CG (2002) A multicenter, randomized, controlled trial comparing Surfaxin (Lumpectant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 109(6):1081–1087
147. Wright JR (2005) Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 5(1):58–68
148. Yost CC, Soll RF (2000) Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2:CD001456
149. Zimmermann LJ, Janssen DJ, Tibboel D, Hamvas A, Camilli VP (2005) Surfactant metabolism in the neonate. Biol Neonate 87 (4):296–307
150. Zuo YY, Alolabi H, Shafiee A, Kang N, Policova Z, Cox PN, Acosta E, Hair ML, Neumann AW (2006) Chitosan enhances the in vitro surface activity of dilute lung surfactant preparations and resists albumin-induced inactivation. Pediatr Res 60(2):125–130